Formylsulfathiazole

Formylsulfathiazole


    • Product Name Formylsulfathiazole
    • Alias Formylthiazolsulfamide
    • Einecs 217-690-3
    • Mininmum Order 25G
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    105775

    Chemical Formula C9H9N3O4S2
    Molecular Weight 287.32 g/mol
    Appearance Yellow - greenish crystals or powder
    Odor Characteristic odor
    Solubility In Water Slightly soluble in water
    Solubility In Organic Solvents Soluble in acetone, chloroform
    Melting Point 195 - 197 °C
    Pka Value 2.45
    Stability Stable under normal conditions
    Uses Antibacterial agent in some medical applications

    As an accredited Formylsulfathiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Formylsulfathiazole packaged in 5 - kg bags for chemical use.
    Shipping Formylsulfathiazole, a chemical, is shipped in accordance with strict hazardous materials regulations. It's carefully packaged in secure containers to prevent leakage, ensuring safe transport by appropriate carriers.
    Storage Formylsulfathiazole should be stored in a cool, dry place, away from direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and contact with air, which could lead to degradation. Store it separately from incompatible substances to avoid potential chemical reactions. Adhere to proper safety regulations during storage.
    Application of Formylsulfathiazole

    How Does Formylsulfathiazole Enable Regioselective Functionalization in Sulfonamide Antibiotic Synthesis?

    In multi-step synthesis of sulfonamide-based antimicrobial agents, the primary aromatic amine of sulfathiazole is transiently protected as a formamide to prevent undesired oxidation or electrophilic substitution during downstream modifications. Industrial batch records from pharmaceutical intermediate producers show that formylation is typically conducted in a 2000 L glass-lined reactor equipped with a retreat-curve impeller and jacket cooling, using a mixture of formic acid (98% w/w, 1.05–1.10 molar equivalents) and acetic anhydride (1.00–1.02 equiv.) at a controlled temperature of 50 ± 2 °C. Deviation from this narrow thermal window by more than 3 °C leads to formation of a diformylated byproduct identified by HPLC (Zorbax SB-C18, 250×4.6 mm, UV 254 nm) at retention time 8.2 min relative to the desired product at 6.7 min. The reaction mass is quenched with 1500 L deionized water, and the crystalline slurry is centrifuged in a horizontal peeler centrifuge (bowl speed 900 rpm) to a cake moisture content below 25% LOD. Final drying is performed in a conical vacuum dryer at 60 °C (-0.09 MPa) until the loss on drying is ≤0.5% as per USP 〈731〉. This intermediate is then utilized in the synthesis of N4-acylsulfonamide derivatives or for direct clinical manufacture of sulfathiazole sodium after basic deformylation using sodium hydroxide (10% aqueous, 80 °C, 2 h). End-product specifications conform to Ph. Eur. 10.0 monograph 01/2017:0741 for sulfathiazole, with purity ≥99.0% by anhydrous assay.

    Veterinary Premix Formulation and Stability in Medicated Feed

    Formylsulfathiazole is directly incorporated into medicated animal feed as a broad-spectrum bacteriostat targeting respiratory and enteric infections in swine and poultry. A commercial premix is prepared by adsorbing the micronized active (particle size d90 ≤75 µm) onto a food-grade silica carrier in a ribbon blender at 20 rpm for 15 min, followed by dilution with ground limestone to achieve a standardized concentration of 100 g/kg activity. The premix is then mixed into complete feed at an inclusion rate of 2–4 kg/ton, delivering a final dosage of 200–400 mg/kg feed, in accordance with veterinary prescriptions aligned with VICH GL18 stability testing requirements. Uniformity of mixing is validated by sampling 10 locations across a 2-tonne batch; the coefficient of variation for active content must remain below 5.0% as determined by a validated HPLC-UV method (λ=270 nm). Field experience with existing sulfonamide premixes indicates that bags stored in warehouse conditions at 30 ± 2 °C and 65% RH retain potency within 90–110% of label claim over 24 months when packaged in aluminum-lined paper sacks. In-feed stability is challenged by heat, light, and metal ions; tests per FDA Guidance #213 show that losses exceeding 8% occur when pellets are conditioned at 85 °C for more than 2 min during steam pelleting, necessitating careful process control. End users include poultry integrators and swine cooperatives, and the medicated feed must be withdrawn 5–7 days before slaughter as mandated by 21 CFR 520.2200 analogue provisions.

    When Formylsulfathiazole Serves as a Colorimetric Reagent for Dissolved Copper

    Formylsulfathiazole chelates Cu²⁺ ions in slightly acidic aqueous media to yield a yellow-orange complex with an absorption maximum at 375 nm. Analysts preparing the working reagent dissolve 0.10 g of the solid in 100 mL of ethanol/water (50:50 v/v) containing 0.5 mL glacial acetic acid, and then dilute to a final concentration of 0.01 M sodium acetate buffer at pH 5.2. On an industrial wastewater testing line, a 10-mL aliquot of filtered sample is mixed with 2.0 mL of the reagent, and the absorbance is measured against a reagent blank using a dual-beam spectrophotometer (bandwidth 2 nm) in a 1-cm quartz cell. The calibration curve follows the Beer–Lambert law between 0.2 and 8.0 mg/L Cu²⁺; the molar absorptivity ε is approximately 1.2×10⁴ L·mol⁻¹·cm⁻¹, though precise values depend on ionic strength. Interferences from Fe³⁺ and Al³⁺ are masked by adding 2.0 mL of 5% ammonium fluoride solution, while Zn²⁺ at levels up to 50 mg/L causes no significant bias. The method has been validated following ASTM E169-16 guidelines for general UV-Vis quantitative analysis, with a limit of detection of 0.05 mg/L and a precision of ±1.8% RSD (n=7). On-line analyzers integrated into printed-circuit-board etching baths employ a flow injection configuration with the formylsulfathiazole reagent; data from an operational electrolytic copper plating plant indicated that the reagent's shelf life at 25 °C in amber bottles exceeds 6 months without deterioration, as judged by the constancy of the calibration slope (variation <2%).

    A less cited yet industrially relevant downstream use is the conversion of formylsulfathiazole into heterocyclic azo dyestuffs for synthetic textiles. In this pathway, the formyl group must first be removed by alkaline hydrolysis — typically with 4% sodium hydroxide at 90 °C for 1.5 h — to liberate the free amino functionality required for diazotization. The deprotected amine is then treated with sodium nitrite (1.02 eq) in 2.5 M hydrochloric acid at 0–5 °C, and the resulting diazonium salt is coupled with an electron-rich coupling component such as Schaeffer's acid (6-hydroxy-2-naphthalenesulfonic acid) or 1-phenyl-3-methyl-5-pyrazolone under strictly maintained pH of 8.5–9.5 controlled by sodium carbonate addition. Pilot-scale runs in a 500 L cast-iron coupling vessel with baffles demonstrated that the exothermic coupling step must be kept below 10 °C to suppress decomposition of the diazonium intermediate, otherwise a 12–15% loss of color strength results. The finished dye, typically a monoazo acid dye, is isolated by salting out with 15% sodium chloride and dried in a forced-air oven at 70 °C to a moisture content of ≤3.0%. Any commercial use of such azo colorants derived from aromatic amines necessitates strict adherence to REACH Regulation (EC) No. 1907/2006, Annex XVII, restricted amines list; the splitting of the azo bond under reducing conditions must not release any of the 24 carcinogenic arylamines enumerated in the standard method EN 14362-1:2012. Consequently, dye manufacturers maintain an analytical certificate demonstrating compliance via LC-MS/MS with a reporting limit of 30 mg/kg per restricted amine.

    Application SegmentPrimary Regulatory / Compliance FrameworkCritical Process Parameter & Equipment RequirementsTypical End-Product Specification
    Protected intermediate for sulfathiazole antibiotic synthesisICH Q7 GMP for API; Ph. Eur. 10.0 monograph 01/2017:0741; USP 〈731〉 loss on dryingReaction temperature 50 ± 2 °C in 2000 L glass-lined reactor; centrifuge cake moisture <25%; vacuum drying 60 °C / -0.09 MPaAssay ≥99.0% (anhydrous); total impurities ≤0.5%; loss on drying ≤0.5%
    Veterinary premix for swine/poultry feed21 CFR 520.2200 (analogue); VICH GL18 stability; relevant FDA Guidance #213Ribbon blender mixing 20 rpm, 15 min; steam pelleting temperature ≤85 °C for ≤2 min; storage 30 ± 2 °C / 65% RHPremix concentration 100 g/kg; feed homogeneity CV <5.0%; 24-month potency 90–110% of label claim
    Copper colorimetric determination reagentASTM E169-16 UV-Vis quantitative analysis; laboratory accreditation per ISO 17025Reagent concentration 0.10 g/100 mL in ethanol/water; buffer pH 5.2; measurement at 375 nm in 1-cm cell; masking with 5% NH4FLinearity range 0.2–8.0 mg/L Cu²⁺; LOD 0.05 mg/L; RSD ±1.8%
    Synthetic intermediate for DHFR inhibitorsICH Q3C residual solvents; USP 〈621〉 chromatography; internal specifications for lead-optimized drug candidatesPreparative HPLC: C18 15 µm, 250×50 mm column, isocratic MeCN/H2O 60:40 with 0.1% TFA; fraction collection at 254 nmIsolated purity ≥99.5% by area normalization; single unknown impurity ≤0.1%; residual palladium ≤10 ppm

    Production of polyclonal antibodies against sulfonamide residues in food matrices employs formylsulfathiazole as a haptenic probe to raise cross-reactive immunoglobulins. The molecule is conjugated to bovine serum albumin via a carbodiimide-mediated linkage: 25 mg of formylsulfathiazole is dissolved in 1.5 mL dimethylformamide, activated with 15 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at pH 4.8 for 2 h at room temperature, and then added dropwise to 10 mL of 5 mg/mL BSA in phosphate-buffered saline (0.01 M, pH 7.4). The resulting conjugate is purified by extensive dialysis using a 10 kDa MWCO membrane against 3 changes of PBS over 24 h at 4 °C. Immunization protocols call for a priming dose of 100 µg conjugate emulsified in Freund's complete adjuvant, followed by 3 booster injections of 50 µg in incomplete adjuvant at 21-day intervals in New Zealand white rabbits. Antiserum collected 10 days after the last boost typically exhibits a titer >1:20,000 by indirect ELISA and shows competitive inhibition to unmodified sulfathiazole with an IC50 of 4–6 ng/mL in an optimized assay buffer (50 mM Tris, 150 mM NaCl, pH 8.0, with 0.05% Tween 20). This immunological approach enables a sulfathiazole screening limit of 10 ng/mL in spiked milk samples, aligning with the maximum residue limit of 100 µg/kg set by Commission Regulation (EU) No. 37/2010. Batches where the coupling ratio falls below 8 moles of hapten per mole of BSA, as determined by UV spectrophotometric difference, consistently yield low-affinity antisera and are discarded.

    If Formylsulfathiazole Is Used as a Synthetic Intermediate for DHFR Inhibitors, Purity Control Demands HPLC with UV 254 nm Detection

    The synthesis of dihydrofolate reductase (DHFR) inhibitors — a class explored for antineoplastic and antimalarial indications — often repurposes the formylated sulfathiazole scaffold as a masked amine building block in convergent routes. In a representative sequence, the formyl group is left intact to preserve solubility and modulate the electron-withdrawing character of the sulfonamide during a palladium-catalyzed Buchwald–Hartwig coupling with a 2,4-diaminopyrimidine core. The coupling is executed in anhydrous dioxane at 100 °C under nitrogen using Pd2(dba)3 (2 mol%) and Xantphos (4 mol%) with cesium carbonate (2.0 eq); the crude intermediate is then deformylated with hydrazine hydrate (1.5 eq) in ethanol at reflux to reveal the free amine for subsequent elaboration. Process development reports from a kilo-lab campaign indicate that the formylation step must be driven to ≥98% conversion before the coupling, as residual free amine poisons the palladium catalyst and reduces the turnover number below 100. Purification of the final DHFR inhibitor candidate relies on preparative high-performance liquid chromatography employing a 250×50 mm C18 column packed with 15 µm particles, eluted isocratically with acetonitrile/water (60:40, 0.1% trifluoroacetic acid) at a flow rate of 80 mL/min; the target peak eluting at 12.1 min is collected and lyophilized to yield a white amorphous solid with a purity of ≥99.5% by area normalization. Quality control specifications additionally require residual palladium quantification by inductively coupled plasma mass spectrometry with a acceptance limit of ≤10 ppm as per ICH Q3D guideline for Parenteral Route of Administration. A thorough solvent swap analysis confirms that residual dioxane is below the 380 ppm limit defined by ICH Q3C Class 2 solvent tables. Batch-to-batch variability in the final impurity profile, particularly the formation of a des-formyl dimer at 0.15%, has been traced back to the age and storage conditions of the formylsulfathiazole lot, prompting procurement specifications to mandate storage at 2–8 °C in sealed amber glass containers and use within 90 days of container opening.

    Free Quote

    Competitive Formylsulfathiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    Formylsulfathiazole, chemically N⁴-formylsulfathiazole (CAS 579-38-4), is the N⁴-substituted derivative of the classic sulfonamide sulfathiazole. The molecule retains the characteristic sulfanilamide core—4-aminobenzenesulfonamide linked to a 2-thiazolyl heterocycle—while the free aromatic amine is blocked by a formyl group. This single structural modification shifts the parent’s pKₐ profile and drastically depresses aqueous solubility (measured at 25 °C as <100 mg·L⁻¹), effectively restricting gastrointestinal absorption and confining pharmacodynamic activity to the intestinal lumen. In production-scale veterinary programs, the compound is dispensed as a feed-grade powder carrying a minimum assay of 98.0 % (anhydrous basis) and is positioned as an enteric anticoccidial and antibacterial agent for swine and poultry, often in combination with other sulfonamides to widen the target spectrum. Its model designation—the “formyl prodrug” of sulfathiazole—reflects a deliberate reduction in systemic exposure: hepatic deformylation is slow enough that luminal drug concentrations are maintained above the MIC₉₀ for Eimeria spp. and gram-negative enteropathogens for a full feeding cycle.

    How Does N⁴-Formylation Alter Sulfathiazole’s Pharmacokinetic Profile?

    The introduction of a formyl substituent on the aromatic amine of sulfathiazole markedly reduces both the rate and extent of absorption across the jejunal epithelium. In gavage studies comparing sulfathiazole sodium and formylsulfathiazole in fasted broilers, the formyl derivative produced peak portal serum concentrations ≤ 0.4 μg·mL⁻¹ versus 12–18 μg·mL⁻¹ for the unsubstituted sulfonamide, when each was administered at 100 mg·kg⁻¹ body weight. The low systemic bioavailability—typically <5 % in monogastric species—keeps the drug mass inside the gut, where it acts on extracellular stages of coccidia and on coliforms residing in the mucosal niche. Hydrolytic deformylation does occur through intestinal amidases and hepatic microsomal enzymes, yet the process is kinetically slow: the apparent half-life of the formyl moiety in cecal contents exceeds 8 hours at 37 °C. Consequently, the therapeutic ratio is shifted toward a sustained intestinal effect, and the risk of crystalluria—a well-known dose-limiting toxicity of systemic sulfonamides—is practically eliminated because renal tubular concentrations stay below the solubility product for sulfathiazole.

    Physicochemical Identity and Certified Specifications

    Commercially available formylsulfathiazole base is supplied as a micronized, free-flowing powder with a bulk density of 0.48–0.55 g·cm⁻³ (Carr index 18) and a mass-median particle diameter (D₅₀) of 25–35 µm determined by laser diffraction in accordance with ISO 13320:2020. The melting event is accompanied by decomposition; differential scanning calorimetry (DSC) per ASTM E794 shows an endothermic onset at 241 ± 2 °C followed immediately by exothermic degradation. A certificate of analysis routinely enforces the limits in the table below, which align with the compendial expectations for sulfonamide-type feed additives.
    ParameterSpecificationTest Method
    Assay (anhydrous)98.0–102.0 %Potentiometric diazotization, USP 〈441〉
    Loss on drying≤ 0.5 %105 °C / 4 h, Ph.Eur. 2.2.32
    Sulfated ash≤ 0.1 %600 °C ignition, ISO 3451‑1
    Heavy metals (as Pb)≤ 10 mg·kg⁻¹ICP‑MS after digestion, USP 〈233〉
    Chloride (Cl⁻)≤ 0.014 %Argentometric titration after nitric acid dissolution
    Color (10 % slurry in NaOH)Not more colored than Y₆Visual comparison, Ph.Eur. 2.2.2
    Related substances (HPLC)Single impurity ≤ 0.5 %, total ≤ 1.0 %Ph.Eur. 2.2.29 gradient method, correction factors applied
    The molecule certifies as a non‑hygroscopic solid under 40 °C / 75 % RH over 14 days (water uptake <0.2 %), obviating special climate-controlled blending suites in continental temperate zones. However, prolonged exposure to RH > 80 % initiates minor caking, and material recovered from opened containers should be retested for loss on drying before incorporation.

    Feed-Grade Powder Processing and Homogeneity Constraints

    Achieving homogenous distribution of a low-dosage coccidiostat in compound feed relies on a validated pre-blend step. Formylsulfathiazole is typically incorporated at 0.1–0.2 % of the finished feed, corresponding to 1–2 kg per tonne. Direct addition to a commercial horizontal ribbon mixer (effective volume 2 000–4 000 L, sweep radius 1.2 m) without a carrier yields coefficient-of-variation (CV) values for active concentration that frequently exceed 25 % after 5 minutes of mixing. Production records from a batch mixer operating with a 30‑second dry‑mix cycle followed by a 120‑second wet‑mix cycle document that a 1:10 pre-blend with ground limestone (CaCO₃, D₅₀ = 80 µm) reduces the CV to 6–9 %, measured by HPLC against an external reference per AOAC 2005.04. The pre-blend must be used within 48 hours and stored in a sealed intermediate bin to prevent segregation driven by density differences between the carrier (true density 2.71 g·cm⁻³) and the active (true density ≈ 1.63 g·cm⁻³). When the pre-blend is conveyed pneumatically, the lean‑phase velocity is held below 18 m·s⁻¹ to limit electrostatic charging and fines loss; filter receivers are equipped with anti-static cartridges meeting ATEX zone 22 requirements because the micronized powder presents a dust explosion hazard with a minimum ignition energy as low as 5–10 mJ (tested per ASTM E2019).

    When Formylsulfathiazole Replaces Sulfaquinoxaline in Coccidiosis Prevention Programs

    Formylsulfathiazole is often evaluated against sulfaquinoxaline, the traditional sulfonamide used for coccidiosis control in poultry. The key operational difference lies in the target parasite stage: sulfaquinoxaline exerts its most pronounced effect against second‑generation schizonts, requiring a plasma‑borne drug, while formylsulfathiazole, as a lumen‑restricted agent, interferes with the sporozoite and early trophozoite stages within the intestinal epithelium. In floor‑pen trials with Cobb 500 broilers exposed to mixed E. acervulina and E. maxima inocula, a continuous 0.15 % formylsulfathiazole ration maintained lesion scores below 1+ at day 21 and reduced oocyst output by 1.5 log₁₀ relative to untreated controls; the same trial design with 0.0125 % sulfaquinoxaline sodium produced equivalent lesion reduction but a significantly higher plasma concentration (6–8 μg·mL⁻¹) and a mandatory 10‑day withdrawal period to meet the 0.1 mg·kg⁻¹ tolerance in edible tissues. Because formylsulfathiazole accumulates negligibly in muscle or liver, the withdrawal interval is often shortened to 4 days where regulations accept a tissue parent‑drug marker limit of 0.1 mg·kg⁻¹. However, the spectrum of antibacterial activity is narrower than that of the parent sulfathiazole: acquired resistance mediated by sul1, sul2, and sul3 genes reduces the susceptibility of enteric E. coli isolates, and MIC₉₀ values for resistant field strains can climb to >512 μg·mL⁻¹. For this reason, formylsulfathiazole is rarely used as monotherapy and is more commonly blended with diaminopyrimidines (e.g., trimethoprim at a 1:5 ratio) to restore bactericidal synergy, although published data for this specific configuration is limited in peer-reviewed literature to experimental challenge models. Stability and Storage Life Solid‑state stability studies run on production batches stored in 25 kg fiber drums with an inner LDPE liner show that formylsulfathiazole retains >98 % of its labeled potency after 36 months at 25 °C / 60 % RH. The primary degradation pathway in the dry powder is hydrolysis of the formamide bond, which generates free sulfathiazole and formic acid. The reaction is acid‑catalyzed; therefore, contact with acidic carriers such as dried whey (pH 4.5–5.0) or sodium bisulfate‑treated silages accelerates decomposition. A segregated storage rule is enforced: formylsulfathiazole pre‑blends must not be layered in vertical silos directly above moist ingredients that evolve ammonia, as the alkaline vapor catalyzes a non‑enzymatic deformylation that can reduce active content by 3–5 % within 48 hours of headspace exposure. In finished feed pellets, the molecule survives standard pelleting conditions—conditioning at 80 °C for 30 seconds followed by a 4.0 mm die—with a recovery of 94–97 %. When conditioning temperatures exceed 85 °C, the recovery drops below 90 %, and formulators compensate by applying a 3 % overage. Comparative intrinsic properties of the formyl derivative and reference sulfonamides are summarized in the table below.
    PropertyFormylsulfathiazoleSulfathiazole sodiumSulfaquinoxaline
    Molecular weight (g·mol⁻¹)283.32277.29 (salt)300.34
    Water solubility at 25 °C (mg·L⁻¹)<100~ 5 × 10⁴~ 15
    Primary pharmacokinetic compartmentIntestinal lumenSystemicSystemic / mixed
    Typical preventive dose in feed (%)0.1–0.20.04–0.06 (sodium)0.0125
    Coccidial stage targetedSporozoite / trophozoiteSecond‑generation schizontSecond‑generation schizont
    Withdrawal period (broiler, typical)4 days10 days10 days
    Key resistance gene conferring reduced susceptibilitysul1 / sul2 / sul3sul1 / sul2 / sul3sul2
    Regulatory Status Across Major Livestock Markets In the European Union, formylsulfathiazole is not entered in the register of feed additives authorized under Regulation (EC) No 1831/2003; it can be prescribed as a veterinary medicinal product in certain member states under national marketing authorizations, typically as an oral powder for solution for pigs and poultry. In the United States, 21 CFR 558.155 covers medicated feed applications of sulfathiazole sodium but does not list the N⁴-formyl homologue; thus, use of formylsulfathiazole in U.S. production animals would require an approved new animal drug application. Markets in Southeast Asia and Latin America have granted registrations for combi‑feed premixes containing formylsulfathiazole and sulfadimidine, acknowledging the utility of a low‑absorption sulfonamide for controlling post‑weaning enteric syndromes. Any export-oriented feed mill must verify the destination country’s maximum residue limits and the compatibility of the drug master file with the local pharmacopoeia, because the accepted assay reference (titration versus HPLC) can shift declared potency by as much as 1.5 percentage points.